The number of biopharma buyouts overall last year did not rise, though more deals were struck in the “sweet spot”, and premiums saw a healthy rise.
Two megamergers meant that 2019 was always going to be a big year for biopharma M&A in dollar terms – and then came a late flurry of deals.
Available to download for free now, our annual preview takes a data-driven look at 2020. Uncover biopharma’s biggest growth drivers, and see where the money is flowing.
Data and M&A lifts buoyant biopharma companies from Fate Therapeutics to Rocket, though on share price gain Forty Seven wins Ash 2019.
Paul Hudson has laid out his vision for Sanofi and it does not include diabetes or me-too products.
The French drugmaker bets big as it plays catch-up in the immuno-oncology space with a next-generation IL-2 buyout.
As Kalvista hopes to attract Merck & Co, Sanofi plays catch-up with Genmab.
The Swiss group does another deal to access a novel technology, taking out the RNAi specialist The Medicines Company.
Two more Orion trials have hit neatly and cleanly, and now success will be largely down to pricing.